Middle Meningeal Artery Embolization for Chronic Subdural Hematoma

Description

Endovascular middle meningeal artery (MMA) embolization is an emerging treatment for chronic subdural hematoma (cSDH). There is preliminary data to suggest that this minimally invasive therapy may be more efficacious and equally as safe compared to conventional, more invasive surgery. This study seeks to assess the safety and efficacy of middle meningeal artery embolization for chronic subdural hematoma as an adjunct to standard treatments, which include medical management and surgical evacuation.

Conditions

Chronic Subdural Hematoma

Study Overview

Study Details

Study overview

Endovascular middle meningeal artery (MMA) embolization is an emerging treatment for chronic subdural hematoma (cSDH). There is preliminary data to suggest that this minimally invasive therapy may be more efficacious and equally as safe compared to conventional, more invasive surgery. This study seeks to assess the safety and efficacy of middle meningeal artery embolization for chronic subdural hematoma as an adjunct to standard treatments, which include medical management and surgical evacuation.

Middle Meningeal Artery (MMA) Embolization for Patients With Chronic Subdural Hematoma (cSDH)

Middle Meningeal Artery Embolization for Chronic Subdural Hematoma

Condition
Chronic Subdural Hematoma
Intervention / Treatment

-

Contacts and Locations

Saint Louis

Washington University School of Medicine, Saint Louis, Missouri, United States, 63108

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Patients 18 years or older undergoing treatment for a new diagnosis of chronic subdural hematoma (cSDH) or
  • * Patients 18 year or older who have undergone surgical evacuation of a subdural hematoma and have a significant residual hematoma status post-surgery or who develop a recurrent subdural hematoma.
  • * Minimal symptoms such as headache, altered mental status, or mild neurological deficit only
  • * Ability to understand and sign written informed consent by patient or LAR
  • * Significant midline shift and/or neurologic symptoms requiring urgent decompression.
  • * Common carotid stenosis of over 50%.
  • * Significant contraindication to angiography (eg. kidney failure, difficult anatomy).
  • * SDH related to underlying condition
  • * Acute SDH

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Washington University School of Medicine,

Joshua W Osbun, MD, PRINCIPAL_INVESTIGATOR, Washington University School of Medicine

Study Record Dates

2025-01-01